To determine the impact of combination therapy on systemic CD8+ T cell responses, we analyzed tumor antigen specific T cells in splenocytes 7 days after the completion of primary tumor treatments, using a PSA-specific MHC Class I pentamer. Here, CD8A is linked to neoplasm.